Boehringer Snaps Up T3 Amid Broader Immuno-Oncology Push

 
• By Alaric DeArment
Boehringer Ingelheim said it would spend up to CHF450m to acquire T3 Pharma • Source: Shutterstock

More from Deals

More from Business